Advancing the Way Heart Failure is Treated
Heart Recovery is Possible With Impella
In a randomized controlled trial, 8-in-10 patients treated with Impella heart pumps experienced reduction in heart failure symptoms or improvement in heart function.2,8 Their native heart function recovered, and heart failure symptoms diminished, such as fatigue, shortness of breath, swelling, and coughing,1,2 in just 90 days after a Protected PCI procedure as compared to other forms of treatment.2
Reduction in Death, Heart Attack and Stroke
in 90-day post-hospitalization as compared to other support methods1
Fewer Repeat Visits
to the hospital for heart-related issues other than traditional therapy3
Fewer Days in the Hospital
after procedure compared to traditional therapy3, 4, 5, 6, 7
Impella is the only U.S. FDA-approved percutaneous heart pump technology indicated for patients with severe coronary artery disease requiring high-risk PCI
References
- Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228.
- O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.
- Gregory, D., et al. (2013). Am Health Drug Benefits, 6(2), 88-99.
- Maini, B., et al. (2014). Catheter Cardiovasc Interv, 83(6), E183-E192.
- Gregory, D., et al. (2013). J Manag Care Med, 16(1), 61-69.
- O’Neill, W.W., et al. (2014). J Interviev Cardiol, 27(1), 1-11.
- Roos, J.B., et al. (2013). J Med Econ, 16(3), 3381-390.
- PROTECT II Data on File
NPS-1760